CCA
GILD icon

Cypress Capital Advisors’s Gilead Sciences GILD Stock Holding History

Cypress Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Buy
1,988
+4
+0.2% +$527 0.1% 73
2026
Q1 		$277K Hold
1,984
– – 0.15% 64
2025
Q4 		$244K Buy
1,984
+12
+0.6% +$1.46K 0.13% 67
2025
Q3 		$219K Buy
1,972
+166
+9% +$18.9K 0.12% 71
2025
Q2 		$200K Buy
+1,806
New +$192K 0.13% 72

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cypress Capital Advisors's GILD Position: Q2 2026 in Review

Cypress Capital Advisors increased its Gilead Sciences (GILD) stake by 0.2% in Q2 2026, buying an estimated $527 and bringing the position to 1,988 shares worth $251K. The position accounts for 0.1% of the portfolio, ranked #73.

Cypress Capital Advisors first reported a position in GILD in Q2 2025 and has held it in 5 quarters since. The position peaked at $277K in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cypress Capital Advisors held 1,988 shares of Gilead Sciences worth $251K as of Q2 2026.
  • Cypress Capital Advisors bought 4 Gilead Sciences shares in Q2 2026, an estimated $527.
  • Gilead Sciences made up 0.1% of Cypress Capital Advisors's portfolio in Q2 2026, its #73 holding.
  • Cypress Capital Advisors first reported a position in Gilead Sciences in Q2 2025 and has held it in 5 quarters since.
  • Cypress Capital Advisors's Gilead Sciences position peaked at $277K in Q1 2026.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cypress Capital Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.